Trial Profile
Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (Phase 1b); Protocol No. P07614
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 05 Feb 2014 Status changed from suspended to discontinued, as per ClinicalTrials.gov record.
- 28 May 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 09 Apr 2013 Planned End Date changed from 1 Nov 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.